Table 2

Risk of hospitalization and death with diabetes (N = 3,385)

Model 1*Model 2Model 3
OutcomeEvents/n at riskHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueP-trend§
Hospitalization
 No diabetes896/2,294RefRefRef<0.001
 Diabetes + no microvascular complication388/7391.49 (1.32, 1.68)<0.0011.18 (1.01, 1.37)0.0361.16 (0.99, 1.35)0.051
 Diabetes + microvascular complications240/3522.30 (1.99, 2.66)<0.0011.54 (1.25, 1.89)<0.0011.52 (1.24, 1.87)<0.001
Hospitalization for heart failure
 No diabetes197/2,294RefRefRef<0.001
 Diabetes + no microvascular complication134/7392.19 (1.76, 2.74)<0.0011.51 (1.14, 1.99)0.00421.46 (1.10, 1.94)<0.001
 Diabetes + microvascular complications106/3523.98 (3.12, 5.08)<0.0011.97 (1.38, 2.80)<0.0011.90 (1.33, 2.72)0.0094
Death
 No diabetes298/2,294RefRefRef0.0017
 Diabetes + no microvascular complication128/7391.51 (1.22, 1.86)<0.0011.35 (1.04, 1.75)0.0251.34 (1.03, 1.74)0.028
 Diabetes + microvascular complications90/3522.29 (1.80, 2.92)<0.0011.73 (1.22, 2.45)0.00191.72 (1.21, 2.43)0.0023
Cardiovascular death
 No diabetes198/2,294RefRefRef0.018
 Diabetes + no microvascular complication79/7391.38 (1.06, 1.80)0.0161.34 (0.96, 1.86)0.0831.33 (0.96, 1.85)0.090
 Diabetes + microvascular complications53/3521.98 (1.45, 2.69)<0.0011.70 (1.09, 2.65)0.0201.68 (1.08, 2.63)0.022
  • *Adjusted for age, sex, and race.

  • †Adjusted for model 1 covariates plus smoking, systolic blood pressure, serum creatinine, BMI, aspirin, ACE inhibitors/angiotensin II receptor blockers, β-blockers, statin, randomization group, New York Heart Association class, coronary heart disease, stroke, prior heart failure hospitalization, insulin, duration of diabetes, and hemoglobin.

  • ‡Adjusted for model 2 covariates plus urine albumin-to-creatinine ratio.

  • §Represents the P-trend across categories. Computed using model 2 covariates.